ART is a leading innovator in the field of the next generation of fully BioResorbable Scaffolds (BRS) that promote the natural remodeling of an injured artery after vascular angioplasty
ART PBS Scaffold
The ART Pure Bioresorbable Scaffold (PBS) is providing effective scaffolding followed by programmed dismantling at around 3 months to enable positive remodeling and complete resorption within 24 months.
The ART PBS is expanded following balloon pre-dilatation of a vascular lesion. After an effective scaffolding period of 3 months, the scaffold dismantles and releases the artery before it completely resorbs.
The ART PBS has been investigated in the multicenter ARTDIVA trial and shown proven scaffolding properties with only 4.3 % angiographic recoil and good drug free BRS long term performances.
A disruptive new technology for the treatment of coronary and peripheral arterial disease
Unique, proprietary PLA platform technology with tunable dismantling, material preserving transformation processes with precise and secure crimping.
Effective scaffolding followed by programmed dismantling at around 3 months to enable positive remodeling and safe complete resorption within 24 months.
In vitro Data
State of the ART in vitro assay development and characterization equipment enhanced strong supportive data for every stage of the bioresorption process.
In vivo Data
Extensive preclinical trial track record with proven safety data from dual GLP animal model investigations with > 250 implantations and up to 36 months follow up.
ART is a leading innovator in the field of the next generation of fully BioResorbable Scaffolds (BRS) that promote
the natural remodeling of an injured artery after vascular angioplasty
Pr. Lafont, interventional cardiologist, and Pr. Vert, world leading expert in bioresorbable polymers, meet and decide after initial academic research to found ART.
Pre 2008, ART focuses efforts on the exploration of various bioresorbable PLA formulas and scaffold concepts.
From 2009 to 2011 development of ART’s first generation bioresorbable scaffold ART PBS, for the most clinically, technically and regulatory demanding indication: coronary angioplasty.
Development plans were established in collaboration with world leading independent experts like, Dr Virmani, Dr Popma and Dr Fajadet.
2012 First implantation on human in Toulouse by Dr Fajadet.
2014 ART signs structured buyout agreement with Terumo, validating ART’s next-gen bioresorbable scaffold.
2015 ART receives CE mark approval for its drug free ART PBS device.
Machiel van der Leest CEO / director
Machiel as a seasoned medical device professional and entrepreneur has developed and introduced over 10 class III devices in the European and global interventional coronary and neurovascular market. In his 15+ years career Machiel held executive positions as CTO and CSO at Nycomed Amersham Medical Systems, Cathnet Science and he co-founded Minvasys. His decisive focus on managing innovation combined with his strong track record, have been the driving forces behind ART since 2009.
Machiel holds a MSc degree from the Technical University Delft, Netherlands, and he is an inventor of over 20 patents.
Pr. Antoine Lafont
Pr. Michel Vert
Dr. Frederick Cornhill
Paris, France, May 21 2015 — Terumo and Arterial Remodeling Technologies (ART) announce that, on May 20, 2015, Dr Renu Virmani, internationally renowned cardiovascular pathologist at CVPath Institute, USA, presented promising pre-clinical data on Terumo’s next generation drug eluting bioresorbable scaffold for the treatment of coronary artery disease. “We are particularly satisfied with the well[…]
Paris, May 18, 2015 – Privately-held company Arterial Remodeling Technologies (“ART”) today announces CE Mark clearance for its next generation drug free, pure bioresorbable scaffold used to treat coronary artery disease. The CE Mark was achieved following the completion of extensive pre- clinical research, including up to three-years of follow-up, and supportive clinical results from[…]
PARIS, March 27, 2014 – Privately held Arterial Remodeling Technologies (‘ART’) announced today that it has signed a structured buyout agreement with Terumo Corporation. Under the agreement, ART and Terumo Corporation will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease. ART[…]
PARIS, July 16, 2012—Arterial Remodeling Technologies (“ART”) reported today that the Company has achieved a medical milestone with its “ARTDIVA” (Arterial Remodeling Transient DIsmantling Vascular Angioplasty) clinical trial: the successful First-in-Human implantation of its novel biodegradable stent into an 61-year-old male who was suffering from a blocked coronary artery and needed a percutaneous coronary intervention[…]
PARIS, May 15, 2012—Arterial Remodeling Technologies (“ART”) reported today that it has received regulatory approval in Europe to begin its First‐In‐Man “ARTDIVA” (Arterial Remodeling Transient DIsmantling Vascular Angioplasty) clinical trial next month at five medical centers. ART’s in vivo data strongly suggest that its next‐generation bioresorbable stent is designed to promote positive arterial remodeling. […]
PARIS, April 4, 2012—Arterial Remodeling Technologies (“ART”) reported today that in vivo data strongly suggest that its next-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at six months follow-up. In addition, acute safety data are promising: there have been more than 300 MACE-free consecutive implantations of its bioresorbable stent in its[…]
PARIS, Nov. 2, 2011—Arterial Remodeling Technologies (“ART”) reported today that in vivo data strongly suggest that its second-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at three months follow- up. In addition, acute safety data are excellent: there have been more than 250 MACE- free consecutive implantations of its bioresorbable stent[…]
PARIS, May 17, 2011—Arterial Remodeling Technologies (“ART”) announced today that details of the state-of-the-art design of its potentially disruptive polymer-based bioresorbable stent platform will be revealed, for the first time, at EuroPCR 2011 from the podium tomorrow (Wednesday, May 18). The disclosure will be presented by Antoine LaFont, M.D., Ph.D., Professor of Medicine, Head Interventional[…]